Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.
Tokyo Medical and Dental University, Department of Molecular Virology, Tokyo, Japan.
J Virol. 2022 Jul 27;96(14):e0065222. doi: 10.1128/jvi.00652-22. Epub 2022 Jun 29.
Human mannose receptor 1 (MRC1) is a cell surface receptor expressed in macrophages and other myeloid cells that inhibits human immunodeficiency virus type 1 (HIV-1) particle release by tethering virions to producer cell membranes. HIV-1 counteracts MRC1 expression by inhibiting transcription. Here, we investigated the mechanism of MRC1 downregulation in HIV-1-infected macrophages. We identified the myeloid cell-specific transcription factor PU.1 as critical for regulating MRC1 expression. In the course of our study, we recognized a complex interplay between HIV-1 Tat and PU.1 transcription factors: Tat upregulated HIV-1 gene expression but inhibited 1 transcription, whereas PU.1 inhibited HIV-1 transcription but activated MRC1 expression. Disturbing this equilibrium by silencing PU.1 resulted in increased HIV-1 gene expression and reduced MRC1 promoter activity. Our study identified PU.1 as a central player in transcriptional control, regulating a complex interplay between viral and host gene expression in HIV-infected macrophages. HIV-1 replication in primary human cells depends on the activity of virus-encoded proteins but also involves cellular factors that can either promote (viral dependency factors) or inhibit (host restriction factors) virus replication. In previous work, we identified human MRC1 as a macrophage-specific host restriction factor that inhibits the detachment of viral particles from infected cells. Here, we report that HIV-1 counteracts this effect of MRC1 by imposing a transcriptional block on cellular MRC1 gene expression. The transcriptional inhibition of the MRC1 gene is accomplished by Tat, an HIV-1 factor whose best-described function actually is the enhancement of HIV-1 gene expression. Thus, HIV-1 has evolved to use the same protein for (i) activation of its own gene expression while (ii) inhibiting expression of MRC1 and other host factors.
人甘露糖受体 1(MRC1)是一种在巨噬细胞和其他髓样细胞中表达的细胞表面受体,通过将病毒粒子束缚在产细胞的质膜上来抑制人类免疫缺陷病毒 1 型(HIV-1)颗粒的释放。HIV-1 通过抑制转录来对抗 MRC1 的表达。在这里,我们研究了 HIV-1 感染的巨噬细胞中 MRC1 下调的机制。我们确定髓样细胞特异性转录因子 PU.1 是调节 MRC1 表达的关键。在我们的研究过程中,我们认识到 HIV-1 Tat 和 PU.1 转录因子之间存在复杂的相互作用:Tat 上调 HIV-1 基因表达,但抑制 1 转录,而 PU.1 抑制 HIV-1 转录,但激活 MRC1 表达。通过沉默 PU.1 扰乱这种平衡会导致 HIV-1 基因表达增加和 MRC1 启动子活性降低。我们的研究确定了 PU.1 作为转录控制的核心参与者,调节 HIV-1 感染的巨噬细胞中病毒和宿主基因表达之间的复杂相互作用。 HIV-1 在原代人细胞中的复制依赖于病毒编码蛋白的活性,但也涉及到可以促进(病毒依赖性因子)或抑制(宿主限制因子)病毒复制的细胞因子。在之前的工作中,我们鉴定了人类 MRC1 作为一种巨噬细胞特异性宿主限制因子,抑制病毒粒子从感染细胞中脱离。在这里,我们报告 HIV-1 通过对细胞 MRC1 基因表达施加转录阻断来对抗 MRC1 的这种作用。MRC1 基因的转录抑制是通过 Tat 完成的,Tat 是 HIV-1 的一个因子,其最著名的功能实际上是增强 HIV-1 基因的表达。因此,HIV-1 已经进化到使用相同的蛋白来(i)激活其自身的基因表达,同时(ii)抑制 MRC1 和其他宿主因子的表达。